|
Aphton says, "Just block it!" The company is developing immunogen-based drugs primarily for the treatment of gastrointestinal cancers. The drugs neutralize or block hormones that play a key role in such diseases as stomach, liver, pancreatic, and prostate cancers, as well as stomach ulcers and gastro-esophageal reflux disease. Aphton has halted work on lead candidate Insegia, an anti-gastrin vaccine to combat pancreatic cancer, because it lacks the funding to continue work. Aphton is shifting its focus to two other cancer drug candidates in early stages of development.
|
| | | Contact Information | |
Address: |
8 Penn Center, 1628 JFK Blvd., Ste. 2300
Philadelphia, PA 19103
| | Phone: | 215-218-4340 | | Fax: | 215-218-4357 |
|
| Financial
Highlights | | Fiscal Year End: | December |
|
|
Key People
| | • |
Chairman, President, and CEO:
Patrick T. (Pat) Mooney
| | • |
SVP, CFO, and Chief Accounting Officer:
James A. (Jim) Smith III
|
|
|
